ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novartis has agreed to invest in, and possibly buy, Gamida Cell, an Israeli company developing stem cell therapies. Novartis will pay $35 million for a 15% stake in Gamida and an option to buy the company if it meets certain clinical milestones by the first half of 2016. If Novartis exercises the option, it will pay another $165 million and up to $435 million in milestone payments. Gamida has a treatment for hematological malignancies, such as leukemia and lymphoma, in early-stage clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter